Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17417590 | 0.99 | KCNH2 (0.77) | KCNH2 | |
| SCHEMBL17417728 | 0.90 | KCNH2 (0.80) | KCNH2 | |
| Hydrochloric Acid SCHEMBL17417718 | 0.89 | KCNH2 (0.78) | KCNH2 | |
| SCHEMBL18084222 | 0.89 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL17417696 | 0.88 | KCNH2 (0.77) | KCNH2 | |
| SCHEMBL17417738 | 0.88 | KCNH2 (1.00) | KCNH2 | |
| Hydrochloric Acid SCHEMBL17417686 | 0.87 | KCNH2 (0.98) | KCNH2 | |
| Hydrochloric Acid SCHEMBL17417763 | 0.87 | KCNH2 (0.76) | KCNH2 | |
| SCHEMBL17417723 | 0.87 | KCNH2 (0.62) | KCNH2 | |
| SCHEMBL17417694 | 0.87 | KCNH2 (0.69) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | KCNH2 355/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | KCNH2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.